Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 0.8%.
The iShares Biotechnology ETF (IBB) climbed 1.4%.
In corporate news, Novartis (NVS) has signed an option and licensing agreement with South Korean biotech Alteogen to develop and sell subcutaneous versions of multiple Novartis drugs using its ALT-B4 technology, Alteogen said Wednesday. Novartis shares rose 0.5%.
Johnson & Johnson (JNJ) is positioned for accelerating growth, supported by a strong pharma pipeline, UBS said in a note. UBS assumed coverage of the stock with a buy rating and a $320 price target. Its shares rose 1.6%.
Alumis (ALMS) shares jumped past 8%. The company's share price drop after the disappointing results of a phase 2b trial of envudeucitinib to treat systemic lupus erythematosus was likely an overreaction, Oppenheimer said in a note. Oppenheimer kept Alumis' outperform rating, while lowering the company's price target to $37 from $55.
Telix Pharmaceuticals (TLX) said it completed patient enrollment for a phase 3 study of its commercial PSMA-PET imaging agents Illuccix and Gozellix in prostate cancer imaging in pre-biopsy setting. Telix shares climbed 5.6%.